• ASLAN Pharmaceuticals

  Participated · Equity · Jul 2016

  ASLAN Pharmaceuticals is a biopharmaceutical company developing ASLAN003 for autoimmune gastrointestinal and skin diseases and certain skin conditions. The company has closed a secured loan facility with K2 HealthVentures providing up to $45 million of secured debt financing. The facility includes a $20 million initial term loan funded at closing and a further $25 million subject to certain terms and conditions. ASLAN intends to use the proceeds to advance the clinical development of ASLAN003 and for general corporate purposes. The company expects to initiate a Phase 2 clinical trial of ASLAN003 in inflammatory bowel disease in early 2022. The loan provides near-term funding to support those planned clinical activities. ASLAN Pharmaceuticals is a biotech focused on developing immunotherapies and targeted agents for tumour types highly prevalent in Asia. Its pipeline comprises four novel therapeutic agents, with lead drug varlitinib currently in phase 2 trials for cholangiocarcinoma, gastric cancer and breast cancer. Proceeds from the new financing will be used to support clinical development of the pipeline. The company said the financing bolsters its financial position and will accelerate progress across its clinical programme. ASLAN has raised over US$100 million to date, including a US$43 million Series C in December 2015 led by Accuron (a Temasek subsidiary). The announcement was released from Singapore and the company is pursuing growth in Taiwan and the region. Aslan Pharmaceuticals is a Singapore-based biotech focused on developing immunotherapies and targeted agents for tumor types prevalent in Asia. The company maintains a proprietary pipeline of four development-stage candidates addressing multiple indications including gastric and breast cancers and inflammatory diseases. Its most advanced programs are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer and trials in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint target, and cMET. Aslan also operates a global medical device and diagnostics division, Accuron MedTech, led by Abel Ang. The company is led by CEO Dr. Carl Firth and plans to use recent proceeds to accelerate clinical development of ASLAN001, which received Orphan Drug Designation in cholangiocarcinoma from the US FDA.

• Eden Biologics

  Participated · Series C · May 2015

  JHL Biotech focuses on developing and manufacturing affordable biologic medicines, with an emphasis on biosimilars, bioengineering and innovative manufacturing solutions. The company provides process development and cGMP manufacturing services and helps global partners access the China market. JHL's pipeline includes proprietary biosimilar compounds and a pre-clinical novel therapeutic portfolio. The company plans to use new funding to continue biosimilar programs through clinical trials, construct a fill-finish facility at its Wuhan commercial manufacturing plant, expand its pre-clinical novel therapeutic portfolio, and support working capital. With the Series C proceeds, JHL has secured capital necessary to complete full development and BLA filing of at least two of its proprietary biosimilar compounds. Founded in 2012 and led by President and CEO Racho Jordanov, the company is based in Hsinchu. Founded in December 2012 and led by President and CEO Racho Jordanov, JHL Biotech focuses on bioengineering and product development under current Good Manufacturing Practices (cGMP). The company has five biosimilar programs and one new molecular entity in development, with an emphasis on biosimilar monoclonal antibodies. It completed construction of a clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has formed partnerships with domestic academic and government institutions as well as regional and global biotech and pharmaceutical companies. JHL plans to submit its first clinical trial and investigational new drug (IND) applications in 2015. Financially, it closed a $35M Series B to fund development of its biosimilar mAb pipeline, accelerate IND filings, support facility expansion in Taiwan, and acquire equipment for a commercial manufacturing facility in Wuhan, China expected to be completed by 2014 year-end. The financing is intended to support both R&D progress and commercial manufacturing build-out.

• Xinhua Travel

  Led · Equity · Sep 2011

  Xinhua Travel is an online tourism service provider in China that aims to build a multi-brand, multi-channel marketing network. The company launched 18 months prior to the report. Its platform has recorded transactions of RMB3 billion (approximately US$462m) since inception. The business reported average monthly revenue growth of more than 120%. Xinhua Travel recently completed a US$23m funding round. Investors include Milestone Capital and other unnamed backers who may invest further based on the company's future development.

• Lashou.com

  Led · Series C · Apr 2011

  Lashou.com is a China-based group-purchasing website that launched daily-deal offerings across several categories. Formally launched in March 2010 in Beijing, it has grown to be one of the largest group-purchasing sites in China. Early product offerings included "Many Groups Per Day", "Lunch Killer Deals by the Seconds", and "Hotel Channels". The company completed a $110M Series C, bringing total capital raised to $166M. Founder and CEO Bo Wu said the new capital will be used to establish and expand call centers, improve the logistics system, and increase customer experience and satisfaction. The company is focusing on scaling operations and customer service to support growth in its marketplace.

No current team members are available.